期刊
ONCOTARGET
卷 8, 期 37, 页码 62730-62741出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.17528
关键词
chimeric antigen receptor; HER2; cancer; immunotherapy; toxicity
资金
- National Science Foundation for Young Scientists of China [81602709, 81502525]
- Natural Science Foundation of Shandong Province [ZR2015YL031, ZR2015PH012]
Given the clinical efficacy of chimeric antigen receptor (CAR)-based therapy in hematological malignancies, CAR T-cell therapy for a number of solid tumors has been actively investigated. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast, as well as other types of cancer. However, HER2 CAR T cells pose a risk of lethal toxicity including cytokine release syndrome from on-target, off-tumor recognition of HER2. In this review, we summarize the development of conventional HER2 CAR technology, the alternative selection of CAR hosts, the novel HER2 CAR designs, clinical studies and toxicity. Furthermore, we also discuss the main strategies for improving the safety of HER2 CAR-based cancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据